RS52375B - Stabilni kristali jedinjenja 4-oksohinolina - Google Patents

Stabilni kristali jedinjenja 4-oksohinolina

Info

Publication number
RS52375B
RS52375B RS20120306A RSP20120306A RS52375B RS 52375 B RS52375 B RS 52375B RS 20120306 A RS20120306 A RS 20120306A RS P20120306 A RSP20120306 A RS P20120306A RS 52375 B RS52375 B RS 52375B
Authority
RS
Serbia
Prior art keywords
crystal
mixture
compound
filtered
added
Prior art date
Application number
RS20120306A
Other languages
English (en)
Serbian (sr)
Inventor
Motohide Satoh
Takahisa Motomura
Takashi Matsuda
Kentaro Kondo
Koji Ando
Koji Matsuda
Shuji Miyake
Hideto Uehara
Original Assignee
Japan Tobacco Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35079161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS52375(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc. filed Critical Japan Tobacco Inc.
Publication of RS52375B publication Critical patent/RS52375B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
RS20120306A 2004-05-20 2005-05-19 Stabilni kristali jedinjenja 4-oksohinolina RS52375B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004150979 2004-05-20
PCT/JP2005/009604 WO2005113508A1 (en) 2004-05-20 2005-05-19 Stable crystal of 4-oxoquinoline compound

Publications (1)

Publication Number Publication Date
RS52375B true RS52375B (sr) 2012-12-31

Family

ID=35079161

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20231092A RS64845B1 (sr) 2004-05-20 2005-05-19 Kombinacija koja se sastoji od stabilnog kristala 4-oksohinolinskog jedinjenja
RS20120306A RS52375B (sr) 2004-05-20 2005-05-19 Stabilni kristali jedinjenja 4-oksohinolina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20231092A RS64845B1 (sr) 2004-05-20 2005-05-19 Kombinacija koja se sastoji od stabilnog kristala 4-oksohinolinskog jedinjenja

Country Status (33)

Country Link
US (7) US7635704B2 (enExample)
EP (4) EP4299563A3 (enExample)
JP (1) JP3754064B2 (enExample)
KR (1) KR20080064909A (enExample)
CN (1) CN1956961B (enExample)
AR (2) AR049280A1 (enExample)
AU (1) AU2005245296B2 (enExample)
BE (1) BE2024C511I2 (enExample)
BR (1) BRPI0510114B8 (enExample)
CA (1) CA2566922C (enExample)
CY (4) CY1113010T1 (enExample)
DK (2) DK3281939T3 (enExample)
ES (2) ES2388441T3 (enExample)
FI (2) FI3281939T3 (enExample)
FR (1) FR23C1040I1 (enExample)
HR (2) HRP20231588T3 (enExample)
HU (2) HUE064615T2 (enExample)
IL (1) IL179250A0 (enExample)
LT (2) LT3281939T (enExample)
LU (1) LUC00334I2 (enExample)
MX (1) MXPA06013405A (enExample)
MY (1) MY134672A (enExample)
NO (8) NO339223B1 (enExample)
NZ (1) NZ551839A (enExample)
PE (2) PE20060358A1 (enExample)
PL (2) PL3281939T3 (enExample)
PT (2) PT1636190E (enExample)
RS (2) RS64845B1 (enExample)
RU (1) RU2330845C1 (enExample)
SI (2) SI3281939T1 (enExample)
TW (1) TWI329015B (enExample)
WO (1) WO2005113508A1 (enExample)
ZA (1) ZA200610647B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891227B2 (en) 2002-03-20 2005-05-10 International Business Machines Corporation Self-aligned nanotube field effect transistor and method of fabricating same
SI1564210T1 (sl) * 2002-11-20 2010-01-29 Japan Tobacco Inc 4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2007063869A1 (ja) * 2005-11-30 2007-06-07 Japan Tobacco Inc. 高純度キノロン化合物の製造方法
AU2013203476C1 (en) * 2005-12-30 2016-11-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
SG170795A1 (en) * 2005-12-30 2011-05-30 Gilead Sciences Inc Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090018162A1 (en) * 2006-02-01 2009-01-15 Yuji Matsuzaki Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
BRPI0708685B8 (pt) 2006-03-06 2021-05-25 Japan Tobacco Inc composto de 4-oxoquinolina, seu uso e método para produção dos mesmos
WO2007102499A1 (ja) 2006-03-06 2007-09-13 Japan Tobacco Inc. ４－オキソキノリン化合物の製造方法
AP2985A (en) 2006-07-07 2014-09-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
CA2661943C (en) 2006-09-12 2015-11-03 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
LT2487163T (lt) * 2007-02-23 2016-10-25 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
EP2167088A1 (en) * 2007-06-29 2010-03-31 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
JP5547067B2 (ja) * 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療組成物およびその使用
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
BRPI0911871A8 (pt) 2008-05-02 2018-03-06 Gilead Sciences Inc uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico
HRP20151009T1 (hr) 2009-02-06 2015-10-23 Gilead Sciences, Inc. Dvoslojna tableta koja sadrži elvitegravir, kobicistat, emtricitabin i tenofovir
WO2010137032A2 (en) * 2009-05-14 2010-12-02 Matrix Laboratories Ltd. Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts
WO2011004389A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
CN102212032B (zh) * 2011-04-20 2013-07-31 复旦大学 一种5-羟基喹诺酮类衍生物及其制备方法和用途
BR112015000187A2 (pt) 2012-07-06 2017-06-27 Genentech Inc benzamidas substituídas com n e métodos de uso das mesmas
EA026089B1 (ru) 2012-08-03 2017-02-28 Джилид Сайэнс, Инк. Способ и промежуточные соединения для получения ингибиторов интегразы
CN103819402B (zh) * 2012-11-17 2016-03-30 上海迪赛诺化学制药有限公司 埃替拉韦中间体及其制备方法和应用
CN103864682B (zh) * 2012-12-18 2016-12-28 上海迪赛诺化学制药有限公司 一种制备iii型埃替拉韦晶体的方法
AU2013361401C1 (en) 2012-12-21 2018-08-09 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
PL3019503T3 (pl) 2013-07-12 2018-01-31 Gilead Sciences Inc Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv
NO2865735T3 (enExample) 2013-07-12 2018-07-21
CN105315203A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种v型埃替拉韦晶体及其制备方法
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (enExample) 2014-06-20 2018-06-23
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CN110790773A (zh) 2015-04-02 2020-02-14 吉利德科学公司 多环氨甲酰基吡啶酮化合物及其药物用途
CN106008195B (zh) * 2016-05-19 2018-08-03 绍兴文理学院 一种2，4-二氟-5-碘苯甲酸的制备方法
EP3984536B1 (en) * 2020-10-19 2025-06-25 Centre national de la recherche scientifique Inhibition of the hiv-1 replication by compounds directed against a new target of the viral cycle

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS567162B1 (enExample) 1970-09-14 1981-02-16
JPS4826772A (enExample) 1971-08-11 1973-04-09
JPS6450979A (en) 1987-08-21 1989-02-27 Hitachi Shipbuilding Eng Co Method for discriminating whistle sound
JPH0651229B2 (ja) 1989-07-31 1994-07-06 新日本製鐵株式会社 プラズマアーク溶接方法および装置
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
NO304832B1 (no) 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JP2993316B2 (ja) 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
JPH06199835A (ja) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体
JPH06271568A (ja) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体
JP2930539B2 (ja) 1994-07-18 1999-08-03 三共株式会社 トリフルオロメチルキノリンカルボン酸誘導体
AU683569B2 (en) 1994-07-18 1997-11-13 Sankyo Company Limited Trifluoromethylquinolinecarboxylic acid derivative
JPH0826772A (ja) 1994-07-22 1996-01-30 Sony Corp 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法
JP4121151B2 (ja) 1996-04-12 2008-07-23 アメリカ合衆国 抗新生物薬および抗レトロウイルス薬として有用なアクリドンから誘導された化合物
FR2761687B1 (fr) 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Ｉｃａｍ−１産生阻害剤
GB9721964D0 (en) 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
PE20011349A1 (es) 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US20050010048A1 (en) 2000-10-12 2005-01-13 Linghang Zhuang Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors
CA2425625A1 (en) 2000-10-12 2002-07-18 Merck & Co., Inc. Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
KR20030078958A (ko) 2001-03-01 2003-10-08 시오노기세이야쿠가부시키가이샤 Ｈｉｖ 인테그라제 저해 활성을 갖는 질소 함유의헤테로아릴 화합물
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
FR2827600A1 (fr) 2001-07-20 2003-01-24 Lipha Derives acides de quinolone et leurs applications en therapeutique
RU2206564C1 (ru) * 2002-03-07 2003-06-20 Общество с ограниченной ответственностью "Поливит" Способ получения этилового эфира 6-фтор-7-хлор-1,4-дигидро-4-оксо-3-хинолинкарбоновой кислоты
JP4035765B2 (ja) 2002-10-31 2008-01-23 横河電機株式会社 フーリエ変換型赤外線分光計
SI1564210T1 (sl) 2002-11-20 2010-01-29 Japan Tobacco Inc 4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze
JP3567162B1 (ja) 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US7531554B2 (en) * 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
EP2332538A1 (en) 2004-05-21 2011-06-15 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents

Also Published As

Publication number Publication date
TWI329015B (en) 2010-08-21
NO20190051A1 (no) 2007-02-07
PE20060358A1 (es) 2006-05-12
CN1956961B (zh) 2010-05-26
CY1113010T1 (el) 2016-04-13
PL3281939T3 (pl) 2024-03-18
NZ551839A (en) 2009-11-27
CN1956961A (zh) 2007-05-02
HUS2400006I1 (hu) 2024-04-28
ZA200610647B (en) 2008-06-25
HUE064615T2 (hu) 2024-04-28
JP3754064B2 (ja) 2006-03-08
AU2005245296B2 (en) 2010-08-12
WO2005113508A1 (en) 2005-12-01
RS64845B1 (sr) 2023-12-29
CY2015009I2 (el) 2024-09-20
US20250091995A1 (en) 2025-03-20
RU2330845C1 (ru) 2008-08-10
US20150361044A1 (en) 2015-12-17
CY2024008I2 (el) 2024-09-20
SI1636190T1 (sl) 2012-09-28
LT3281939T (lt) 2023-11-27
PT3281939T (pt) 2023-11-22
CY1126560T1 (el) 2024-09-20
LUC00334I2 (enExample) 2024-07-01
BRPI0510114B1 (pt) 2020-09-15
BRPI0510114B8 (pt) 2021-05-25
ES2388441T3 (es) 2012-10-15
PL1636190T3 (pl) 2012-10-31
CA2566922A1 (en) 2005-12-01
EP4299563A2 (en) 2024-01-03
EP3281939A1 (en) 2018-02-14
EP1636190A1 (en) 2006-03-22
JP2006001927A (ja) 2006-01-05
FI3281939T3 (fi) 2023-10-23
AR096100A2 (es) 2015-12-09
US7635704B2 (en) 2009-12-22
US20180029989A1 (en) 2018-02-01
NO339223B1 (no) 2016-11-21
CA2566922C (en) 2011-01-11
NO20240384A1 (no) 2007-02-07
NO20161297A1 (no) 2007-02-07
US8981103B2 (en) 2015-03-17
US20060030710A1 (en) 2006-02-09
NO20220690A1 (no) 2007-02-07
FR23C1040I1 (fr) 2023-12-29
MXPA06013405A (es) 2007-03-01
DK1636190T3 (da) 2012-09-24
US20190185433A1 (en) 2019-06-20
TW200600097A (en) 2006-01-01
NO20230913A1 (no) 2007-02-07
LTPA2024001I1 (enExample) 2024-04-10
HRP20120681T1 (hr) 2012-09-30
CY2015009I1 (el) 2024-09-20
AR049280A1 (es) 2006-07-12
EP4299563A3 (en) 2024-02-28
NO20065790L (no) 2007-02-07
NO2024034I1 (no) 2024-07-15
NO20200873A1 (no) 2007-02-07
BE2024C511I2 (enExample) 2024-10-08
DK3281939T3 (da) 2024-01-22
FIC20240008I1 (fi) 2024-03-20
EP2514746A1 (en) 2012-10-24
EP3281939B1 (en) 2023-10-18
EP1636190B1 (en) 2012-06-27
AU2005245296A1 (en) 2005-12-01
KR20080064909A (ko) 2008-07-09
SI3281939T1 (sl) 2024-02-29
HRP20231588T3 (hr) 2024-03-15
ES2960824T3 (es) 2024-03-06
CY2024008I1 (el) 2024-09-20
NO347902B1 (no) 2024-05-06
MY134672A (en) 2007-12-31
US20100204271A1 (en) 2010-08-12
PT1636190E (pt) 2012-08-20
BRPI0510114A (pt) 2007-09-25
LTC3281939I2 (enExample) 2025-04-25
PE20120361A1 (es) 2012-05-03
US20220235009A1 (en) 2022-07-28
IL179250A0 (en) 2007-03-08
HK1083341A1 (en) 2006-06-30

Similar Documents

Publication Publication Date Title
US20250091995A1 (en) Stable crystal of 4-oxoquinoline compound
NO327098B1 (no) 4-oksokinolin forbindelser, anvendelser derav, farmasoytiske sammensetninger samt kommersielle forpakninger
JP2005002092A (ja) ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
US7745459B2 (en) Quinolizinone compound and use thereof as HIV integrase inhibitor
KR100866296B1 (ko) ４―옥소퀴놀린 화합물의 안정한 결정체
HK1083341B (en) Stable crystal of 4-oxoquinoline compound
RU2275361C2 (ru) Соединение 4-оксохинолина и его применение в качестве ингибитора вич интегразы